Health Topics — Endocrine, Reproductive & Limbic
The Endocannabinoid System and the HPG Axis: What Research Has Examined
CB1 receptors sit on the neurons that pulse-release GnRH — the hormone that sets the entire reproductive cascade in motion. What preclinical research has found about ECS modulation of the HPG axis, and what that means for CBG and CBD research in this domain.
The HPG axis begins with a pulse. GnRH neurons in the hypothalamus fire in a rhythmic pattern — too fast or too slow and the pituitary stops responding, and the reproductive hormone cascade either stalls or collapses. CB1 receptors are expressed directly on the neurons that govern that pulse. That proximity is why the ECS belongs in this research conversation.
Kisspeptin — The Master Regulator of GnRH Pulsatility
GnRH neurons do not fire spontaneously in isolation. Their pulsatile activity is governed by a population of upstream neurons in the hypothalamus that produce kisspeptin — a neuropeptide discovered in 2003 and now recognized as the master regulator of reproductive hormone output. Kisspeptin neurons integrate signals from nutritional status, stress hormones, gonadal steroids, light-dark cycles, and body weight, and translate all of this into a coordinated instruction to GnRH neurons: pulse now, or wait. Disruption of kisspeptin signaling — whether through malnutrition, chronic stress, extreme exercise, or pharmacological interference — suppresses GnRH pulsatility and downstream reproductive hormone output.
CB1 receptors are expressed on kisspeptin neurons and on GnRH neurons themselves. This dual expression means the ECS can influence reproductive hormone output at two upstream points in the cascade — at the kisspeptin level, modulating the instruction to GnRH neurons, and at the GnRH neuron level directly. The functional significance of this architecture has been examined primarily in animal models, with findings that are consistent but not yet translated to human research.
ECS Receptor Distribution in the HPG Axis
Preclinical Evidence — What Animal Studies Have Found
LH Suppression (Consistent Finding): Multiple animal model studies across species — rodents, primates — have documented that cannabinoid administration suppresses LH secretion. The mechanism involves both reduced GnRH pulse frequency and reduced pituitary responsiveness to GnRH. This is among the most robustly replicated findings in cannabinoid-reproductive research, though it has been documented primarily with THC and synthetic cannabinoids. Whether hemp-derived cannabinoids at physiological concentrations produce the same degree of LH suppression is not established.
Endogenous ECS Tone and Fertility: Studies using CB1 knockout mice — animals engineered without functional CB1 receptors — show altered reproductive timing: earlier puberty onset, altered estrous cyclicity, and modified LH surge patterns compared to wild-type animals. Loss-of-function evidence of this kind establishes that endogenous CB1 signaling is involved in normal reproductive timing. It does not establish what exogenous cannabinoids do to this system.
Follicular Fluid Anandamide (Human Observational): The most relevant human data comes from IVF research: anandamide concentrations in follicular fluid correlate with oocyte quality and fertilization outcomes. Women with higher follicular fluid anandamide show better IVF outcomes in some studies; elevated anandamide has also been associated with implantation failure in others. These observational findings are complex, inconsistent across studies, and do not support directional recommendations about cannabinoid use and fertility.
CBD and CBG Specifically: Neither CBD nor CBG has been directly studied for effects on LH, FSH, GnRH pulsatility, or gonadal hormone production as of 2026. The preclinical HPG axis literature is dominated by THC, synthetic CB1 agonists, and endocannabinoid system manipulation through enzyme inhibition — not phytocannabinoids. Extrapolating THC findings to CBD or CBG is not supported given their substantially different receptor profiles.
The Direction Problem — Suppression vs. Modulation
Most cannabinoid-HPG research has examined suppressive effects: CB1 activation reducing GnRH, LH, and testosterone. This raises a question the research has not resolved: is endocannabinoid tone in the HPG axis primarily inhibitory, or does it modulate the axis in a bidirectional, context-dependent way — as it does in many other systems?
In stress contexts, elevated endocannabinoid tone may restore HPG axis output that has been suppressed by cortisol — by reducing CRH-driven HPA activation that would otherwise further suppress GnRH. In this framing, endocannabinoid signaling could support reproductive function under stress by limiting the HPA-HPG interference described in the pillar anchor. Whether exogenous cannabinoids reproduce this effect, and at what doses, has not been studied.
The Honest Evidence Summary
CB1 receptors are expressed at multiple nodes of the HPG axis — on kisspeptin neurons, GnRH neurons, pituitary gonadotrophs, ovarian cells, and Leydig cells in the testes. Preclinical evidence consistently documents that CB1 activation suppresses LH secretion and downstream gonadal hormone production. Loss-of-function animal studies establish that endogenous ECS tone is involved in normal reproductive timing. Follicular fluid anandamide data provides limited human observational evidence of ECS involvement in ovarian function.
CBD and CBG have not been studied for direct effects on HPG axis hormone levels as of 2026. The preclinical suppression findings are primarily THC-based and should not be extrapolated to non-psychoactive cannabinoids without specific evidence. The direction of ECS influence on the HPG axis — suppressive, modulatory, or context-dependent — is not fully resolved. This remains an area of genuine research interest with significant gaps.
References
- Gammon, C.M., Freeman, G.M., Xie, W., et al. (2005). Regulation of gonadotropin-releasing hormone secretion by cannabinoids. Endocrinology, 146(10), 4491–4499.
- Karasu, T., Marczylo, T.H., Maccarrone, M., & Konje, J.C. (2011). The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility. Human Reproduction Update, 17(3), 347–361.
- Maccarrone, M., Bari, M., Lorenzon, T., et al. (2000). Anandamide inhibits human sperm motility and their acrosome reaction. Fertility and Sterility, 74(3), 553–559.
- Navarro, M., Hernández, E., Muñoz, R.M., et al. (1997). Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses and prolactin secretion in the rat. NeuroReport, 8(2), 491–496.
- Roth, M., Obaidat, A., & Hagenbuch, B. (2012). OATPs, OATs, and OCTs: The organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. British Journal of Pharmacology, 165(5), 1260–1287.
- Skorupskaite, K., George, J.T., & Anderson, R.A. (2014). The kisspeptin-GnRH pathway in human reproductive health and disease. Human Reproduction Update, 20(4), 485–500.
- Walker, O.S., Holloway, A.C., & Raha, S. (2019). The role of the endocannabinoid system in female reproductive tissues. Journal of Ovarian Research, 12(1), 3.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.